Bleomycin Sulfate

製品コードS1214 別名:NSC125066

Bleomycin Sulfate化学構造

分子量(MW):1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 M2LLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHSRmszOOLCk{GwNFAh|ryv NILJUnczPCCqwrC= NG\jU3ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NVjSTXc5OjZyOEi3NVE>
POLK WT MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP MYOyOlA{OTRyMB?=
POLK KO NGr2foJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jVcGlEPTB;ND6wN-KBkcLz4pEJNU46OsLizszN NInSfZEzPjB|MUSwNC=>
POLK CD MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTVwNUpihKnDueLCiUGuNFDDqM7:TR?= NYXkXYRiOjZyM{G0NFA>
RLE/Abca3 NXzaOHpbTnWwY4Tpc44hSXO|YYm= M2rBU|AvPMLizszN NG\BZYIyPDUEoHi= NYO2SJh7cW6mdXPld{BiKG2xcoDoc4xw\2mlYXygZ4hidmenIH\yc40h\XCrdHjlcIlidC2uaXvlJI1wenCqb3zv[5khfG9iYTD3bYRmNCC|cILlZYQud3W2IH3vdpBpd2yxZ4pCpC=> MYGyOVc3ODV|OB?=
PMCs M3PqW2Z2dmO2aX;uJGF{e2G7 M2ryTFAvOeLCk{NCpO69\y:vbB?= MXKyOOKhcA>? MWTjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? M2D4UFI2PTl3NkSy
PMCs MXnGeY5kfGmxbjDBd5NigQ>? NG\yPJcxNjMEoN88[{9udA>? M2XxbFI16oDVN{NCpIg> NEnGe|NqdmS3Y3XzJIlv[3KnYYPld{BqdiC4aX3lcpRqdiCjbnSg{tEuW02DIIDyc5RmcW5? NUTGbZFZOjV3OUW2OFI>
PMCs M{i1UGZ2dmO2aX;uJGF{e2G7 M1q1OVAvOsLizsznM41t MWe3NkBp MmrRbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv MmH5NlU2QTV4NEK=
PMCs NUnzdHFQTnWwY4Tpc44hSXO|YYm= M1HUVVAvOsLizsznM41t NHfKVJUyOi9{ND:0PEBp NXzaNot4cW6lcnXhd4V{KGOnbHygcYloemG2aX;u NH6wVm0zPTV7NU[0Ni=>
IMR-32 NUHIWXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLTO{426ojUMUKwJOK2\y:vbB?= NEPWeXoyOuLKkkS4JIg> NGHyS49KSzVyPU[wJOK2\y:vbDDheEB1cGViZX7kJI9nKDJ2IHjyd{Bw\iCrbnP1ZoF1cW:w Ml73NlU2OzZ|NEW=
HT1080 NI\zcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:xJO69VQ>? NHvOW4UzPCCqwrC= NVjuOXJqdGWjZIOgeI8h[SCJMj;NJIRmdGG7 MWeyOVUyQDl4MR?=
HT1080 NYHFTJVHTnWwY4Tpc44hSXO|YYm= NI\OSowyKM7:TR?= MlzDNlQhcMLi MnH1bY5lfWOnczDhJJBwfGWwdDDncI9j[WxiRF7BJIRidWGpZTDy[ZNxd26|ZR?= NHTLPJQzPTVzOEm2NS=>
HDFn MmL6R5l1d3SxeHnjbZR6KEG|c3H5 NXi3Oo4xPzJiaB?= NFTaO|hKSzVyPUmuN|EmyqB? NUHkZ405OjV{N{[3PVI>
THP-1 NX3GRZROS3m2b4TvfIlkcXS7IFHzd4F6 M{\PS|czKGh? MUHJR|UxRTRwN{el M1T2OVI2Ojd4N{my
HT-29 M1riZ2N6fG:2b4jpZ4l1gSCDc4PhfS=> MYG3NkBp M2LGdmlEPTB;MUGuOFkm NWSwO|dNOjV{N{[3PVI>
HCT116  M2W4dWN6fG:2b4jpZ4l1gSCDc4PhfS=> MYq3NkBp NWPONXpnUUN3ME2xNU4{PCV? MoLINlUzPzZ5OUK=
A431 NUfQSW9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG4dY82OC1{MECgTXU> M4LUe|Q56oDLaB?= Mn;ObY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4G3VFI2OTBzMkm5
T24 M2S0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvkV286PTBvMkCwJGlW NYfCeXQ2PDkkgJno MVLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NV7SSGFjOjVzMEGyPVk>
AY-27  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HuRlUxNTJyMDDJWS=> MoW3OFjjiImq M2[4XolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NH;iVoozPTFyMUK5PS=>
A549 Ml7nSpVv[3Srb36gRZN{[Xl? M1TuTVEhyrWpL33MxsA> M13wRlAuPDhiaB?= MYfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> NFe1TG8zPDl4M{[zOS=>
MLE12 M4m5VmZ2dmO2aX;uJGF{e2G7 MnTCNUDDvWdxbV|CpC=> M4O1XVAuPDhiaB?= M1nqe4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C MoryNlQ6PjN4M{W=
Jurkat NXKzXnMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTaNlDjiIoQvH2= NUnRTIpsOjUkgJnoxsA> MULhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> NETaR2QzPDlzNki5Ny=>
HeLa  MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13wOWlEPTB;MUCuNuKh|ryP Mnv3NlQ4OzJ|OUe=
C18-4 M4nFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTPVHFROC1zMECg{txO NEHvO3ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 Mn:3NlQ2PzF7OEK=
BMG-1  MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi0NE85OMLizsznM40> NYrqdmtQO8LiaB?= NUDVWpg1cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NVeyV2FwOjN7ME[3NlY>
A459 NV\2eGFYSXCxcITvd4l{KEG|c3H5 MXOxNEBuXQ>? M2nDNlQ5KGh? MYLpcoR2[2W|IHHwc5B1d3Orcx?= Mk\zNlM6ODJ5Nk[=
MOCK MVzBdI9xfG:|aYOgRZN{[Xl? NIXCTnkyOCCvVR?= M4DLWlQ5KGh? NVHxflE5cW6mdXPld{BieG:ydH;zbZM> NVrXbHNpOjN7MEK3OlY>
MMP1 NVTHR4pkSXCxcITvd4l{KEG|c3H5 M4PFcFExKG2X MmH4OFghcA>? MYTpcoR2[2W|IHHwc5B1d3Orcx?= NUjlV|FWOjN7MEK3OlY>
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOyNFAh|ryP MlTqNlQhcMLi M1e2W4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NH7WZ|kzOzhyNUe5Ny=>
HCT-116 MYHBdI9xfG:|aYOgRZN{[Xl? MlLqN{84NjVxMUWg{txoN22u M1u1SVQ5KGh? MlnVdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NXPUcZR4OjN5MEi2Olg>
HeLa M1XFd2Fxd3C2b4Ppd{BCe3OjeR?= NH7iR2M{NzdwNT:xOUDPxGdxbXy= MXW0PEBp NVq4U2t3emWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? MoK4NlM4ODh4Nki=
HCT116 NUPaVFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXleIcxNTFyMDFOwIcwdWx? MXy0PEBp M2XPNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{[zW|I{PTF6MkCx
NCM460 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlflNE0yODBizsznM41t NGXjWFc1QCCq MXPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M4LXSVI{PTF6MkCx
NT2  NFniSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPYNlQhcMLi NWmxXpJMVER3ME20NFDjiIoEtXevcYw> MYSyN|M5PjR{MB?=
NT2  NEfMXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG0PEBp NEPWfIVNTDVyPUGwNEDDvWdxbXy= NVPVT4NjOjN|OE[0NlA>
NT2  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O1fVczKGh? NXvUbI1tVER3ME2yNQKBkcL3Zz;tcC=> MonPNlM{QDZ2MkC=
NT2  M3PudmFxd3C2b4Ppd{BCe3OjeR?= NYHHSGpsPDBy4pEJxtVoN22u MWeyOEBpyqB? NVv1T|lEcW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi MmHRNlM{QDZ2MkC=
NTera-2 MlvUSpVv[3Srb36gRZN{[Xl? MXyxNlAh|rypL33s MYW3NkBp M3PtbZNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NFH6[lIzOjh{NUO1OS=>
NCCIT M1fkb2Z2dmO2aX;uJGF{e2G7 NH;MZnoyOjBizsznM41t MXq3NkBp M1PJdZNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NXXXcGI3OjJ6MkWzOVU>
NTera-2 MkTnSpVv[3Srb36gRZN{[Xl? M2rKPVEzOCEQvHevcYw> M3nvXFczKGh? MWfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCWQlHSV{Bt\X[nbIO= NFzydlYzOjh{NUO1OS=>
NCCIT NV\lNlR6TnWwY4Tpc44hSXO|YYm= NETmeYsyOjBizsznM41t MnftO|IhcA>? NIf4co1{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> MXeyNlgzPTN3NR?=
NCCIT NHL5WGhHfW6ldHnvckBCe3OjeR?= MnvaNVIxKM7:Zz;tcC=> M1;nSFczKGh? NEGx[41{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDHV2ghdGW4ZXzz MXSyNlgzPTN3NR?=
NTera-2 NEXXcVZHfW6ldHnvckBCe3OjeR?= NUjvelV7OTJyIN88[{9udA>? M1ntPFczKGh? NHXwOXN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? NHGybY4zOjh{NUO1OS=>
NCCIT MlT0SpVv[3Srb36gRZN{[Xl? NVq1S4loOTJyIN88[{9udA>? MVy3NkBp Mlfwd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MVSyNlgzPTN3NR?=
NTera-2 M1rYT2Z2dmO2aX;uJGF{e2G7 M3\n[lEzOCEQvHevcYw> NYnEW4JNPzJiaB?= Mo\rd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= MXOyNlgzPTN3NR?=
NCCIT MWnGeY5kfGmxbjDBd5NigQ>? NYfId5c1OTJyIN88[{9udA>? NELid244OiCq NF;pdmp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MoW0NlI5OjV|NUW=
MDA-MB-468 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzqUJRbOOLCk{KwNOKh|rypL33M MV6yOEBp M2HGcolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MViyNlgyQTF7Nh?=
231-H2N NG\MbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\HcJpGOOLCk{KwNOKh|rypL33M NY[4OpBiOjRiaB?= MoPjbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mof3NlI5OTlzOU[=
A549  NUjIUGJ1TnWwY4Tpc44hSXO|YYm= MnL0NlAxNzRyMDFOwG0> MYny[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= NES0fnEzOjd5M{[5Oy=>
A549  NGLFS|JHfW6ldHnvckBCe3OjeR?= NXLENGZ{OC12MECg{txO MV:yMVQ5KGh? MUTjZZV{\XNibX;y[UBufESQQTD0bIFvKG6GTlGg[IFu[Wen NV;0PZZ3OjJ5N{O2PVc>
A549  NHTmUlVHfW6ldHnvckBCe3OjeR?= M1jWVlExOCEQvF5CpC=> M{fiPFDjiJN2ODDo Mn\hZ4F2e2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u NHO3WGozOjd5M{[5Oy=>
A549  M{e5PWZ2dmO2aX;uJGF{e2G7 M4e0W|ExOCEQvF5CpC=> M3\I[|DjiJN2ODDo NF;IWphk[XW|ZYOgVGtFOSClbHXheoFo\Q>? M{Lq[VIzPzd|Nkm3
A549  NXH3TpZwTnWwY4Tpc44hSXO|YYm= NVnuVmE4OTByIN88UeKh MnPZNQKBmzR6IHi= M4SzUINifXOnczDtbZRw[2ixbnTybYFtKGyxY3HsbZpifGmxbjDv[kBD[Xh? MoPtNlI4PzN4OUe=
A549  MmTWSpVv[3Srb36gRZN{[Xl? NIOxdWgyODBizszNxsA> M{TlSFDjiJN2ODDo M17tcYRm[3KnYYPld{BOVVBiYX7kJGFVWCCuZY\lcJM> MWmyNlc4OzZ7Nx?=
MCF-7/Her-18  NH[1eohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H0RVAvPDJvMUewNEDPxGdxbVy= NHmzSpUzPCCq NV7w[JpZcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NYXzdWF{OjJ4MkG0NFQ>
MCF-7 MYrQSHQwWEOLIGTy[YF1dWWwdB?= MkHrNE4zPSEQvHevcYwv MWWxMVQhcA>? M3LUVZNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> M33iSFIzPTlzMki0
MDA-MB-231 M2jk[XBFXC:SQ1mgWJJm[XSvZX70 MlX3NE4zPSEQvHevcYwv NGXneZAyNTRiaB?= NWTaXXl{e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MViyNlU6OTJ6NB?=
MDA-MB-235  NH;wcIlRTFRxUFPJJHRz\WG2bXXueC=> M4nYW|AvOjVizsznM41tNg>? M4LFdFEuPCCq NG[4SIN{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 MoO2NlI2QTF{OES=
MCF-7 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjy[IsxNTJizsznM41tNg>? M2nJeFI1NzR6IHi= NGjGdldGSzVyPUGuNkDPxGdxbVy= NHrRPHozOjV7MUK4OC=>
NCCIT  NXq4bFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPsNlDjiJNzNEFCpO69\y:vbB?= NWrSZnJYPzJiaB?= MWHMSFUxRTF{MNMg{txoN22uwrC= NX;2W|JQOjJ3NkKxOlA>
NCCIT  MVjGeY5kfGmxbjDBd5NigQ>? NFHpZnA4OiCq MkK5d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NYXvT2dMOjJ3NkKxOlA>
NCCIT  Mo\BSpVv[3Srb36gRZN{[Xl? MYm3NkBp NFnCWJp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> NWr3[4UyOjJ3NkKxOlA>
NCCIT  MVvGeY5kfGmxbjDBd5NigQ>? NE[zNoE4OiCq M2XibJNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg M1vsWVIzPTZ{MU[w
NCCIT  M1nTVmZ2dmO2aX;uJGF{e2G7 M{nQclczKGh? NHG4clJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= MkjDNlI2PjJzNkC=
NCCIT  Mo\NSpVv[3Srb36gRZN{[Xl? MXq3NkBp NH\xcIR{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhSmOuLUKgZ49vfGWwdB?= NHPKXpQzOjV4MkG2NC=>
NCCIT  MV;GeY5kfGmxbjDBd5NigQ>? M1z6OVczKGh? Ml\rd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt NXnEbItOOjJ3NkKxOlA>
HeLa NY\5[ZN1TnWwY4Tpc44hSXO|YYm= MV2zNE84OCEQvHevcYw> MYKyOOKhcA>? MYjpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> Mm\HNlI1QDd7M{e=
MCF-7  NVmwR2huTnWwY4Tpc44hSXO|YYm= MVyzNE84OCEQvHevcYw> M33pN|I1yqCq NIXyXIJqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NXjLcHd[OjJ2OEe5N|c>
HeLa MWXDfZRwfG:6aXPpeJkhSXO|YYm= NYnhUFdCOzBxN{Cg{txoN22u MorrNlTDqGh? NYK1TVdscW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt Mli5NlI1QDd7M{e=
MCF-7  M2S2eWN6fG:2b4jpZ4l1gSCDc4PhfS=> NIS2SI4{OC95MDFOwIcwdWx? NVH2c4FROjUEoHi= M4joWolv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= M1j0N|IzPDh5OUO3
NT2 NH7pdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\VNVAxNTZyMNMg{txoN22u NV7lOoZ2OjRiaB?= NGLGV3hKSzVyPUSwNEDDvWdxbXy= M4PUdVIzPDZ7OUWy
NT2 MomxSpVv[3Srb36gRZN{[Xl? M4j5WlQxOMLizsznM41t M1HHNVI1KGh? NH;nd5h{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? NEfQZZIzOjR4OUm1Ni=>
NT2 NFzsXXRHfW6ldHnvckBCe3OjeR?= MlvTOFAxyqEQvHevcYw> MnzRNlQhcA>? NHniWYJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= NF73bVUzOjR4OUm1Ni=>
NT2 NFHFSplHfW6ldHnvckBCe3OjeR?= MUK0NFDDqM7:Zz;tcC=> NYHL[lU6OjRiaB?= MYTzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?= NX;YTpNVOjJ2Nkm5OVI>
CHO NUXUVXJ6TnWwY4Tpc44hSXO|YYm= Mk\jNk42yqEQvHevcYw> NVzwcJJkOThiaD:2JIQ> M{TJWIlv\HWlZYRCpJBmenOrc4TlcoNmKG:oIHPodo9ud3OxbXWg[IFu[Wen Mo\uNlIzOzBzOUW=
Jurkat NVnveoNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PMb|AuOTBywrFOwIcwdWx? NHruPYwzPCCq MVvhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> Mn3JNlIzOjN|M{K=
Jurkat NX20Wnc{TnWwY4Tpc44hSXO|YYm= MVSzNOKh|rypL33s M17Z[lI1KGh? NF7xbVRqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIHP5Z4xqdnNiREOsJGEh[W6mIFKx M{\ITVIzOjJ|M{Oy
Jurkat MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTyNE0yODEEoN88[{9udA>? M3Tkd|I1KGh? MnLWbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? MYiyNlIzOzN|Mh?=
Jurkat MWTGeY5kfGmxbjDBd5NigQ>? MkToN|DDqM7:Zz;tcC=> MWeyOEBp MknXbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? MnXWNlIzOjN|M{K=
U2OS EGFPnls MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G4elAuOsLizsznM41t MmXwNlQhcA>? NXLvboNUcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NFr5S|QzOThzMUCwOy=>
U2OS KuEnls NV\xdHpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHvNE0zyqEQvHevcYw> NV3wdJl7OjRiaB?= MoPMbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXnxO2NrOjF6MUGwNFc>
MCF-7 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nIR|AuPDByIN88US=> MX63NkBp M2jRdGxEPTB;MUWxMljDqM7:TR?= MXGyNVcxOzJ7MR?=
MCF-7/Adr  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13xfVAuPDByIN88US=> NF:1TlQ4OiCq MXrMR|UxRTV6LkZCpO69VcLi Mn;xNlE4ODN{OUG=
WI-38 MkGxSpVv[3Srb36gRZN{[Xl? MViwM|QxNzhy4pEJ{txoN22uwrC= M3PRdFMhcA>? M3vuWIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NHnjO4ozOTV7OU[xNi=>
hBMSC NETvNFFHfW6ldHnvckBCe3OjeR?= M4i3WVAwPDBxOEFihKnPxGdxbX|CpC=> NHL6Spg{KGh? M3;zPIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NELCbmIzOTV7OU[xNi=>
NCI-H23 MmLMSpVv[3Srb36gRZN{[Xl? MkPNNE81OC96MPMAje69\y:vbNMg NIDHcpE{KGh? NIPPTphqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MWWyNVU6QTZzMh?=
A-549 NHW5flhHfW6ldHnvckBCe3OjeR?= NWKxWmlrOC92MD:4NQKBkc7:Zz;tcOKh MYKzJIg> MmSwbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MXuyNVU6QTZzMh?=
PBL  NH7zVplHfW6ldHnvckBCe3OjeR?= MUOwM|QxNzhy4pEJ{txoN22uwrC= MmLjN{Bp MWnpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg NYfkOnpZOjF3OUm2NVI>
pol β −/− MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TKZ|AvOjVvMkCwxsDPxGdxbXy= MmDKNlTDqGh? NXHiOoZC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MXmyNVI2OTl2NB?=
pol β +/+ MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K2S|AvOjVvMkCwxsDPxGdxbXy= M3fUTVI1yqCq MkLR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh NEP3W|czOTJ3MUm0OC=>
pol β −/− NYLnNlZTTnWwY4Tpc44hSXO|YYm= Mlz2NE0zNjVizsznM41t NWToSYJFOiCq NV;Id49Y[2G3c3XzJGRPSSCmYX3h[4U> M4e3PVIyOjVzOUS0
pol β +/+ NVjofo5MTnWwY4Tpc44hSXO|YYm= MYKwMVIvPSEQvHevcYw> M3HNcFIhcA>? M1nkZoNifXOnczDEUmEh\GGvYXfl M1W1e|IyOjVzOUS0
pol β −/− NFPjVI9HfW6ldHnvckBCe3OjeR?= NWPV[HVEOC13IN88[{9udA>? MYC0PEBp MnjTZ4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NHnybo8zOTJ3MUm0OC=>
pol β +/+ M1G3VWZ2dmO2aX;uJGF{e2G7 M{\FcVAuPSEQvHevcYw> NVrSeYpQPDhiaB?= Mn[5Z4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M2fQZlIyOjVzOUS0
TK6  M4rMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLnNlUuOTVyIN88[{9udA>? NVLyV2NwQTZiaB?= NImw[IlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MVGyNVA5OTR6Nx?=
TK6  sLUC+Apn1 NVv2WYliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPNNlUuOTVyIN88[{9udA>? MVm5OkBp M3;KZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{j0eFIyODhzNEi3
TK6 sAPE1+Apn1 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiyOU0yPTBizsznM41t M4WwdFk3KGh? M1H1eZNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= MYSyNVA5OTR6Nx?=
HCT116 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjwZZVFOjVvMUWwJO69\y:vbB?= M2\IVFk3KGh? NGDCe5dqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MnPxNlExQDF2OEe=
HCT116 sLUC+Apn1 NX3tSnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\wXVI2NTF3MDFOwIcwdWx? M4\3WVk3KGh? Ml\xbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Ml;TNlExQDF2OEe=
HCT116 sAPE1+Apn1 NWDoO3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOyOU0yPTBizsznM41t NELtSJM6PiCq NUfkXodHe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXOyNVA5OTR6Nx?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

+ 展開
  • 細胞株: ADIPO-P2 cells
  • 濃度: 2.5 μg/mL
  • 反応時間: 30 minutes
  • 実験の流れ:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD-1 mice
  • 製剤: Saline
  • 投薬量: 5 mg/kg, 2 ml/kg
  • 投与方法: Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4

CAS No. 9041-93-4
保管
in solvent
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Children''s Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01132807 Completed Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 8 2010 Phase 2
NCT01026220 Completed Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Children''s Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID